Peptides Vietnam LogoPeptides Vietnam
Back to Guides
ComparisonWeight LossChecked 16 Nov 2026

Mazdutide vs Retatrutide

Mazdutide vs retatrutide is a match of two receptors against three. Mazdutide hits GLP-1 and glucagon. Retatrutide hits those two plus GIP.

Mazdutide is already approved in China. Retatrutide had no record in a Drugs@FDA search on 16 November 2026 (we did not check every country) and is still in phase 3. Our ClinicalTrials.gov search found no trial that puts the two side by side, so the results below come from separate trials. We read each one on 16 November 2026 and give its name, arm, length and size, so you can see what each figure is and is not.

Survodutide, another dual agonist from a different company, gets its own section further down.

On this page

How do mazdutide, retatrutide and survodutide compare at a glance?

ItemMazdutideRetatrutideSurvodutide
Receptors hitGLP-1 and glucagon (dual)GIP, GLP-1 and glucagon (triple)Glucagon and GLP-1 (dual)
CompanyInnovent Biologics, developed with Eli LillyEli Lilly (funder of the TRIUMPH-1 trial)Boehringer Ingelheim
Latest trial phasePhase 3 (GLORY-1, GLORY-2)Phase 3 (TRIUMPH program)Phase 3 (SYNCHRONIZE program)
Where approvedChina: weight management from June 2025, type 2 diabetes from September 2025No approval found in Drugs@FDA on 16 November 2026 (other countries not checked); a pre-approval expanded access record is openNo approval found in Drugs@FDA on 16 November 2026 (other countries not checked). Called investigational in its October 2026 NEJM paper
Trial weight changeGLORY-2 (JAMA 2026): 9 mg arm, 60 weeks, -16.65% vs -1.50% on placebo, 461 treated in total (307 mazdutide, 154 placebo)TRIUMPH-1 (NEJM 2026): 12 mg arm, 80 weeks, -25.0% vs -3.9% on placebo, 2,339 randomizedSYNCHRONIZE-1 (NEJM 2026): 6.0 mg arm, 76 weeks, -13.0% vs -5.4% on placebo, 725 randomized
Gap over placebo-15.15 points (as reported)-21.0 points (as reported)-7.6 points (our subtraction)
Who was studiedChinese adults with a BMI of 30 or more, 16.1% with type 2 diabetesAdults with obesity, no diabetesAdults with a BMI of 30 or more, or 27 or more with a weight problem, no diabetes

Read the columns apart, not across. Each weight figure is the highest dose arm of that drug's newest weight trial. The trials differ in length (60, 80 and 76 weeks), in who took part, and in how they counted people who stopped treatment. The gap over placebo is the drug arm minus the placebo arm. For survodutide we did that sum ourselves: -13.0 minus -5.4 is -7.6 points. Its placebo group lost 5.4%, more than the other two placebo groups, which is one more reason the rows do not line up.

Disclaimer: the 9 mg, 12 mg and 6.0 mg figures in this table are the trial arms named, given under medical supervision and reported as averages. They do not tell anyone what to take, and a licensed prescriber is the right person for any decision about these drugs.

Sources: GLORY-2, Gao et al., JAMA, 4 August 2026 (PMID 42251595); TRIUMPH-1, Jastreboff et al., New England Journal of Medicine, 5 November 2026 (PMID 42814954); SYNCHRONIZE-1, le Roux et al., New England Journal of Medicine, 20 August 2026 (PMID 42253238); Mazdutide: First Approval, Drugs, December 2025 (PMID 41028652); ClinicalTrials.gov, pre-approval expanded access of retatrutide, NCT07629401; SYNCHRONIZE-2, Wharton et al., New England Journal of Medicine, 1 October 2026 (PMID 42820639); openFDA Drugs@FDA query for retatrutide, mazdutide and survodutide, 16 November 2026

Has anyone tested mazdutide against retatrutide?

No. On 16 November 2026 we searched ClinicalTrials.gov for any study that lists both mazdutide and retatrutide. It returned none. A second search for survodutide with retatrutide also returned none.

That matters more than any single number. A head to head trial gives two drugs to people inside one study and counts the results with one shared method. Without one, a bigger average can come from a longer trial, a heavier group, or a different way of handling dropouts, rather than from the drug.

What differsGLORY-2 (mazdutide)TRIUMPH-1 (retatrutide)
Length60 weeks80 weeks
WhoChinese adults, BMI 30 or more, mean age 33.9Adults with obesity and no diabetes
Diabetes allowedYes, 16.1% had type 2 diabetesNo
How results were countedEveryone who got at least one doseTreatment-regimen estimand, counting people whether or not they stayed on the drug
Placebo arm result-1.50%-3.9%

Sources: ClinicalTrials.gov search for trials listing both mazdutide and retatrutide, and both survodutide and retatrutide, 16 November 2026; GLORY-2, Gao et al., JAMA, 4 August 2026 (PMID 42251595); TRIUMPH-1, Jastreboff et al., New England Journal of Medicine, 5 November 2026 (PMID 42814954)

What does dual vs triple agonist mean?

An agonist is a molecule that switches a receptor on. A dual agonist switches on two kinds. A triple agonist switches on three.

  • Mazdutide: GLP-1 and glucagon. Its papers call it a GLP-1 and glucagon receptor dual agonist.
  • Survodutide: the same pair, glucagon and GLP-1, in a different molecule from a different company.
  • Retatrutide: GIP, GLP-1 and glucagon. TRIUMPH-1 calls it a triple hormone receptor agonist.

So the one thing retatrutide has that the other two lack is GIP. Retatrutide also shares glucagon with mazdutide. This page does not credit any result to one receptor.

For the receptor story in more depth, see our GLP-3 explainer, and the compound pages for mazdutide, retatrutide and survodutide. The two receptor comparison with tirzepatide is in retatrutide vs tirzepatide.

Sources: GLORY-1, Ji et al., New England Journal of Medicine, 12 June 2025 (PMID 40421736); SYNCHRONIZE-1, le Roux et al., New England Journal of Medicine, 20 August 2026 (PMID 42253238); TRIUMPH-1, Jastreboff et al., New England Journal of Medicine, 5 November 2026 (PMID 42814954)

What did each trial test, and what did it find?

In the published trials listed below, these were the weekly dose arms each one tested and the mean weight change each arm reported. They are what each trial gave its groups under medical watch, set out as the papers report them.

TrialDrugPublishedPeopleWeeksWeekly arms testedMean weight change, same order
GLORY-1MazdutideNEJM, June 2025610 Chinese adults, mean weight 87.2 kg484 mg, 6 mg, placebo-11.00%, -14.01%, +0.30%
GLORY-2MazdutideJAMA, August 2026461 Chinese adults, mean weight 94.0 kg609 mg, placebo-16.65%, -1.50%
US phase 2MazdutideLancet Diabetes Endocrinol, 2026179 US adults without diabetes32 (primary)3 to 6 mg, 10 mg, 16 mg, placebo-7.3%, -15.6%, -18.1%, -0.9%
TRIUMPH-1RetatrutideNEJM, November 20262,339 adults with obesity, no diabetes804 mg, 9 mg, 12 mg, placebo-17.6%, -23.7%, -25.0%, -3.9%
SYNCHRONIZE-1SurvodutideNEJM, August 2026725 adults, mean weight 108.8 kg, no diabetes763.6 mg, 6.0 mg, placebo-12.2%, -13.0%, -5.4%
SYNCHRONIZE-2SurvodutideNEJM, October 2026752 adults with type 2 diabetes763.6 mg, 6.0 mg, placebo-8.2%, -9.8%, -3.9%

Disclaimer: these are trial arms under medical supervision, reported as averages. They do not tell anyone what to take or when, and no single person should expect the average. A licensed prescriber is the right person for any decision about these drugs.

A few details sit behind the table. GLORY-1 had two main goals measured at week 32, where the 6 mg arm was at -12.55%. The table shows its week 48 figures. In the US mazdutide trial, run by Eli Lilly, the 3 to 6 mg arm stayed on 3 mg until week 32, and its main result used a hypothetical estimand, which estimates the effect as if everyone had stayed on treatment. So it is not counted the same way as the treatment-policy results in the table.

Trial arms are not the same as the math for a vial. For the mixing arithmetic (mg, mL and syringe units), our retatrutide calculator shows the math without saying what anyone should take, and the retatrutide dosage guide walks through what TRIUMPH tested in more detail.

Sources: GLORY-1, Ji et al., New England Journal of Medicine, 12 June 2025 (PMID 40421736); GLORY-2, Gao et al., JAMA, 4 August 2026 (PMID 42251595); Mazdutide US phase 2, Hsia et al., Lancet Diabetes and Endocrinology, November 2026 (PMID 42628555); TRIUMPH-1, Jastreboff et al., New England Journal of Medicine, 5 November 2026 (PMID 42814954); SYNCHRONIZE-1, le Roux et al., New England Journal of Medicine, 20 August 2026 (PMID 42253238); SYNCHRONIZE-2, Wharton et al., New England Journal of Medicine, 1 October 2026 (PMID 42820639)

What side effects did the trials report?

All three trial programs name stomach and gut effects as the most common reported side effects. The figures each paper gives in its summary are below. Each trial counted them its own way, so they are not a ranking.

  • Mazdutide, GLORY-2: vomiting in 53.1% on 9 mg vs 1.3% on placebo, nausea 46.9% vs 3.2%, diarrhea 39.4% vs 6.5%. Side effects made 2.9% stop the drug, against 0% on placebo.
  • Mazdutide, GLORY-1: side effects led 1.5% on 4 mg and 0.5% on 6 mg to stop, against 1.0% on placebo.
  • Mazdutide, US phase 2: stopping for side effects was highest on 16 mg, at 20%, mainly for gut problems.
  • Retatrutide, TRIUMPH-1: the summary says the most common side effects were gastrointestinal. It gives no rates in the summary, so we quote none.
  • Survodutide, SYNCHRONIZE-1: gut side effects in 80.9% on 3.6 mg and 89.7% on 6.0 mg, against 47.9% on placebo.

For how these effects are discussed across the GLP-1 class, see our GLP-1 side effects guide. What any of it means for one person is a question for a doctor.

Sources: GLORY-2, Gao et al., JAMA, 4 August 2026 (PMID 42251595); GLORY-1, Ji et al., New England Journal of Medicine, 12 June 2025 (PMID 40421736); Mazdutide US phase 2, Hsia et al., Lancet Diabetes and Endocrinology, November 2026 (PMID 42628555); TRIUMPH-1, Jastreboff et al., New England Journal of Medicine, 5 November 2026 (PMID 42814954); SYNCHRONIZE-1, le Roux et al., New England Journal of Medicine, 20 August 2026 (PMID 42253238)

Where does survodutide fit in survodutide vs retatrutide?

Survodutide is another dual agonist. It hits glucagon and GLP-1, the same pair as mazdutide, and is made by Boehringer Ingelheim. Its October 2026 NEJM paper calls it investigational, and a Drugs@FDA search on 16 November 2026 returned no record for it. We did not check every country.

Its two main weight trials, SYNCHRONIZE-1 and SYNCHRONIZE-2, ran for 76 weeks. In people without diabetes the 6.0 mg arm reached -13.0%. In people with type 2 diabetes it reached -9.8%, and in that 6.0 mg arm blood sugar (HbA1c) fell 0.8 points from a starting level of 7.4%.

Survodutide also has a finished heart safety trial. SYNCHRONIZE-CVOT, published in The Lancet on 9 November 2026, followed 5,507 treated adults for a median of 22 months. Its main endpoint combined death from heart causes, non-fatal stroke, non-fatal heart attack, artery-opening procedures for blocked heart arteries, and heart failure events. It happened in 3.7% on survodutide and 4.1% on placebo, a hazard ratio of 0.89 (95% CI 0.67 to 1.18). That met the trial's goal of showing the drug was not worse than placebo on that combined endpoint. For retatrutide, the matching trial, TRIUMPH-Outcomes (NCT06383390), is listed on ClinicalTrials.gov as active and not recruiting, with a primary completion date listed as February 2029.

As with mazdutide, our ClinicalTrials.gov search found no study that tests survodutide against retatrutide.

Sources: SYNCHRONIZE-1, le Roux et al., New England Journal of Medicine, 20 August 2026 (PMID 42253238); SYNCHRONIZE-2, Wharton et al., New England Journal of Medicine, 1 October 2026 (PMID 42820639); SYNCHRONIZE-CVOT, The Lancet, 9 November 2026 (PMID 43003106); ClinicalTrials.gov, TRIUMPH-Outcomes, NCT06383390; ClinicalTrials.gov search for trials listing both mazdutide and retatrutide, and both survodutide and retatrutide, 16 November 2026

Which of them is approved, and where?

CompoundStatus we found, 16 November 2026Source and its limits
MazdutideApproved in China (brand Xinermei): June 2025 for weight management, September 2025 for type 2 diabetesA review in Drugs (December 2025). We did not read the Chinese regulator record itself.
RetatrutideNo approval found. A pre-approval expanded access program is listed as availableDrugs@FDA returned no record; ClinicalTrials.gov NCT07629401. We did not check every country.
SurvodutideNo approval found. Called investigational in its October 2026 trial paperNEJM, 1 October 2026; Drugs@FDA returned no record. We did not check every country.

One link between two of them is easy to miss. Eli Lilly funded TRIUMPH-1, the retatrutide trial, and the Drugs review names Lilly as a development partner of Innovent on mazdutide. Lilly also ran the US phase 2 trial of mazdutide. So Lilly has a hand in the trials of both the dual and the triple agonist on this page.

For the retatrutide filing timeline, see when will retatrutide be available. This guide's one store link, for retatrutide, goes to Peptara Labs. No price is quoted here.

Sources: Mazdutide: First Approval, Drugs, December 2025 (PMID 41028652); ClinicalTrials.gov, pre-approval expanded access of retatrutide, NCT07629401; openFDA Drugs@FDA query for retatrutide, mazdutide and survodutide, 16 November 2026; SYNCHRONIZE-2, Wharton et al., New England Journal of Medicine, 1 October 2026 (PMID 42820639); Mazdutide US phase 2, Hsia et al., Lancet Diabetes and Endocrinology, November 2026 (PMID 42628555)

Frequently Asked Questions

What is the difference between mazdutide and retatrutide?+

Mazdutide hits two receptors, GLP-1 and glucagon. Retatrutide hits three, adding GIP to those two. Mazdutide is made by Innovent Biologics, developed with Eli Lilly, and has been approved in China since June 2025. Its TRIUMPH-1 trial was funded by Eli Lilly, and, as of 16 November 2026, we found no approval for it. We searched Drugs@FDA and the trial papers, not every country. It is still in phase 3 trials.

Is retatrutide stronger than mazdutide?+

Nobody can say from a trial yet, because our search found no trial that tested the two against each other. On 16 November 2026 ClinicalTrials.gov listed no study that includes both. The biggest published averages come from separate trials: retatrutide 12 mg gave -25.0% at 80 weeks in TRIUMPH-1, and mazdutide 9 mg gave -16.65% at 60 weeks in GLORY-2. Those trials ran for different lengths of time in different groups of people, so the gap between them is not a measured difference between the drugs.

Has there been a head to head trial of mazdutide vs retatrutide?+

No. A ClinicalTrials.gov search on 16 November 2026 for studies listing both mazdutide and retatrutide returned none. The same search for survodutide and retatrutide also returned none. Every comparison on this page lines up separate trials.

Where is mazdutide approved?+

In China. A review in the journal Drugs reports that mazdutide, sold as Xinermei, was approved in China in June 2025 for long term weight management in adults, and in September 2025 to help manage type 2 diabetes in adults. We found no approval for it in the US: a Drugs@FDA query on 16 November 2026 returned no record.

Is retatrutide approved anywhere?+

We found no approval. A Drugs@FDA query on 16 November 2026 returned no record for retatrutide, and ClinicalTrials.gov lists a record for it titled pre-approval expanded access. Our page on when retatrutide may be available follows the filing timeline.

How does survodutide compare with retatrutide?+

Survodutide is a dual agonist like mazdutide, hitting glucagon and GLP-1, and is made by Boehringer Ingelheim. In SYNCHRONIZE-1, adults without diabetes on the 6.0 mg arm changed weight by -13.0% at 76 weeks, against -5.4% on placebo. Its cardiovascular safety trial, SYNCHRONIZE-CVOT, reported in The Lancet in November 2026 that it met its safety goal against placebo. Our ClinicalTrials.gov search on 16 November 2026 found no study that tests survodutide against retatrutide.

Are mazdutide and survodutide the same thing?+

No. They are different molecules from different companies that hit the same two receptors, glucagon and GLP-1. Their trials used different doses, lengths and groups of people, so their results cannot be swapped for each other.

Does Peptara Labs sell mazdutide or survodutide?+

This page makes no claim that it does. The one store link on this page is for retatrutide, and it is the only compound we point to there. For any other compound, check the store listing itself.

Sources: ClinicalTrials.gov search for trials listing both mazdutide and retatrutide, and both survodutide and retatrutide, 16 November 2026; GLORY-2, Gao et al., JAMA, 4 August 2026 (PMID 42251595); TRIUMPH-1, Jastreboff et al., New England Journal of Medicine, 5 November 2026 (PMID 42814954); Mazdutide: First Approval, Drugs, December 2025 (PMID 41028652); openFDA Drugs@FDA query for retatrutide, mazdutide and survodutide, 16 November 2026; ClinicalTrials.gov, pre-approval expanded access of retatrutide, NCT07629401; SYNCHRONIZE-1, le Roux et al., New England Journal of Medicine, 20 August 2026 (PMID 42253238); SYNCHRONIZE-CVOT, The Lancet, 9 November 2026 (PMID 43003106)

Education, not medical advice

This page sets published trial results side by side. It does not say which compound anyone should use, and it promises no result. Talk to a licensed doctor before any decision about these drugs.

Related Guides

Sources

  1. 1.GLORY-1, Ji et al., New England Journal of Medicine, 12 June 2025 (PMID 40421736)
  2. 2.GLORY-2, Gao et al., JAMA, 4 August 2026 (PMID 42251595)
  3. 3.Mazdutide US phase 2, Hsia et al., Lancet Diabetes and Endocrinology, November 2026 (PMID 42628555)
  4. 4.Mazdutide: First Approval, Drugs, December 2025 (PMID 41028652)
  5. 5.TRIUMPH-1, Jastreboff et al., New England Journal of Medicine, 5 November 2026 (PMID 42814954)
  6. 6.ClinicalTrials.gov, pre-approval expanded access of retatrutide, NCT07629401
  7. 7.SYNCHRONIZE-1, le Roux et al., New England Journal of Medicine, 20 August 2026 (PMID 42253238)
  8. 8.SYNCHRONIZE-2, Wharton et al., New England Journal of Medicine, 1 October 2026 (PMID 42820639)
  9. 9.SYNCHRONIZE-CVOT, The Lancet, 9 November 2026 (PMID 43003106)
  10. 10.ClinicalTrials.gov, TRIUMPH-Outcomes, NCT06383390
  11. 11.ClinicalTrials.gov search for trials listing both mazdutide and retatrutide, and both survodutide and retatrutide, 16 November 2026
  12. 12.openFDA Drugs@FDA query for retatrutide, mazdutide and survodutide, 16 November 2026